WELCOME TO ACTELION’S AGM 2015 · Chairman of the Board . Business Review 2014 : Jean-Paul Clozel, Chief Executive Officer : André Muller, Chief Financial Officer . Agenda & Proposals

Copyright © 2015 Actelion Pharmaceuticals Ltd

WELCOME TO ACTELION’S AGM 2015

08 May 2015

© 2015 Actelion Pharmaceuticals Ltd

MEETING STRUCTURE

ACTELION’S ANNUAL GENERAL MEETING 2015

Opening Remarks Jean-Pierre Garnier, Chairman of the Board

Business Review 2014 Jean-Paul Clozel, Chief Executive Officer André Muller, Chief Financial Officer

Agenda & Proposals Jean-Pierre Garnier, Chairman of the Board Marian Borovsky, Secretary of the Board of Directors

Annual General Meeting 2015 08 May 2015 2


FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING



IHR ePAD / YOUR ePAD

Ja Oui Yes

Nein Non

No

Enthaltung Abstention Abstention



FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING


© 2015 Actelion Pharmaceuticals Ltd Annual General Meeting 2015 08 May 2015 6

OPENING REMARKS BY THE CHAIRMAN OF THE BOARD

Jean-Pierre Garnier


Jan-14 Apr-14 Jul-14 Oct-14 Jan-15 Apr-15

ACTELION SHARE PRICE PERFORMANCE

Annual General Meeting 2015 7 08 May 2015

ACTELION

SWISS SMI

AGM 2014

Selexipag results

Share price development +53% in 2014

SNB announcement


> CHF 1 BILLION RETURNED TO SHAREHOLDERS OVER 3 YEARS

DELIVERING ON OUR STRATEGY CREATES VALUE

08 May 2015 Annual General Meeting 2015 8

SHARE PRICE PERFORMANCE DIVIDEND PAYMENT

0.8 1.0

1.2

2012 2013 2014


2015 INITIATIVES

CONTINUED CASH RETURNED TO SHAREHOLDERS


New second-line share repurchase: up to 10 million shares within 3 years

Increased dividend: Board proposal CHF 1.30 per share


OPENING REMARKS BY THE CHAIRMAN OF THE BOARD

Jean-Pierre Garnier


OUTSTANDING PERFORMANCE IN 2014

Jean-Paul Clozel, CEO


ACHIEVEMENTS 2014: WE ARE ON TRACK

OUR STRATEGIC PRIORITIES STAY THE SAME


BUILD ADDITIONAL SPECIALTY

FRANCHISES

OPTIMIZE PROFITABILITY

SUSTAIN AND GROW THE PAH

FRANCHISE






FRANCHISES



FRANCHISE


FRANCHISE


ENGINE OF TRANSFORMATION

OPSUMIT®


Opsumit (macitentan) is an orally available endothelin receptor antagonist (ERA) approved for the treatment of PAH in over 30 countries, including the United States in October 2013 and the European Union in December 2013

© 2015 Actelion Pharmaceuticals Ltd 08 May 2015 Annual General Meeting 2015 15

Selexipag (Uptravi) is an investigational drug submitted to health authorities

but not approved for use

OPEN THE PROSTACYCLIN PATHWAY TO MORE

PATIENTS


COVERING CONTINUUM OF CARE WITH OUTCOME-BASED MEDICINES

UNIQUELY POSITIONED TO SERVE PAH


FC III FC II FC IV

* Selexipag (Uptravi) is an investigational drug submitted to health authorities but not approved for use.


PROMISING PROJECTS TO DELIVER FUTURE SUCCESS

OUR CARDIOVASCULAR PIPELINE


Selexipag PAH Macitentan Eisenmenger syndrome Macitentan CTEPH Macitentan CpcPH Selexipag Raynaud’s 2o to SSc New Chemical Entity Cardiovascular disorders

Phase I Phase II Phase III Filing






FRANCHISES



FRANCHISE


FRANCHISES


SPECIALTY PRODUCT PORTFOLIO



PROMISING PROJECTS TO DELIVER FUTURE SUCCESS

OUR SPECIALTY PIPELINE


Cadazolid Clostridium difficile assoc. diarrhea Ponesimod Multiple Sclerosis Ponesimod Graft vs. host disease S1P1 modulator Systemic lupus erythematosus Lucerastat Fabry disease Macitentan Glioblastoma New Chemical Entity Neurological disorders

Phase I Phase II Phase III Filing






FRANCHISES



FRANCHISE





Strong sales performance

Good cost control

Markedly increased earnings per share

Strong balance sheet assuring financial flexibility

Total shareholder return of 55%

ACHIEVEMENTS 2014

© 2015 Actelion Pharmaceuticals Ltd 08 May 2015 Annual General Meeting 2015 23

OBTAIN regulatory approval for selexipag (Uptravi)

DRIVE shareholder value creation

INITIATE and ADVANCE key clinical programs

MAINTAIN successful Opsumit launch momentum

2015 – FOCUS ON EXECUTION


STRONG FINANCIAL PERFORMANCE IN 2014

André C. Muller, CFO


FULL YEAR 2014 – FINANCIAL OVERVIEW


Variance

FY 2013 FY 2014 CHF CER

Product sales CHF million

1,784 1,956 10% 12%

Core earnings CHF million

619 743 20% 25%

Operating income CHF million

482 570 18% 24%

Core EPS CHF

4.41 5.58 27% 33%


PRODUCTS SALES GROWTH OF 12%, INTRINSIC GROWTH OF 10%

FULL YEAR 2014 – PRODUCT SALES


1,784 1,956 1,956

181 42 51

FY '13 Sales FY '14 intrinsic sales growth

US rebate reversals FX FY'14 Sales

CHF million


TRANSITIONING

FY 2014: STRONG COMMERCIAL PERFORMANCE


Opsumit + CHF 175 million

Tracleer - CHF 43 million

Veletri + CHF 28 million

Ventavis + CHF 0.2 million

Zavesca + CHF 9 million

Others + CHF 12 million

Total + CHF 181 million

US + CHF 85 million

Europe + CHF 66 million

Japan + CHF 16 million

RoW +CHF 14 million

Total + CHF 181 million


CORE EARNINGS UP 25% AT CER

FY 2014 – CORE EARNINGS


1,956 1,375

743

212 369

631

2014 Product sales Core COS Core R&D Core SG&A 2014 Core earnings

CHF million


FY 2014 – NET INCOME


CHF million

743 570 537 479 479

594

173 33

58 115

FY'14 Coreearnings

Non-core items FY '14 OperatingIncome

Financial result Income taxexpense

One timedeferred tax

benefits

FY '14 NetIncome


FY 2014 – CASH FLOW


CHF million

878 1,036

1,512

966 1,205

616 458 609 133

546 249

10

Unrestrictedgross cash31 Dec 13

Operatingcash flow

(ex litigation)

Litigationpayment

Releasedrestricted cash

Dividend 1st line sharepurchase

Proceeds fromESOP

Capex, otheritems

Unrestrictedgross cash31 Dec 14


Q1 2015 – FINANCIAL OVERVIEW


Variance

Q1 2014 Q1 2015 CHF CER

Product sales CHF million

469 515 10% 12%

Core earnings CHF million

189 218 15% 18%

Operating income CHF million

153 190 24% 28%

Core EPS CHF

1.46 1.61 10% 12%


AT CONSTANT EXCHANGE RATES

2015 FINANCIAL GUIDANCE


Core earnings growth low double-digit percentage range (excl. 2014 US rebate reversals)


CONCLUDING REMARKS BY THE CHAIRMAN OF THE BOARD


Documents

WELCOME TO ACTELION’S AGM 2015 · Chairman of the Board . Business Review 2014 : Jean-Paul Clozel, Chief Executive Officer : André Muller, Chief Financial Officer . Agenda & Proposals